Abstract: Provided are an isolated binding protein including an antigen binding domain of cardiac troponin I (cTnI), as well as a preparation and uses of the binding protein. The antigen binding domain includes at least one complementary determining region selected from the amino acid sequences defined herein; or the antigen-binding domain has at least 80% sequence identity with the complementary determining regions of said amino acid sequences and has an affinity for cardiac troponin I of KD?3.33×10?8 mo/L. The binding protein may be used in the field of cTnI protein detection.

Abstract: Provided is an isolated binding protein including an antigen-binding domain that binds to NS1 protein. The isolated binding protein includes specific heavy chain CDRs and light chain CDRs. The binding protein can specifically recognize and bind to NS1, and has relatively high sensitivity and specificity, thereby achieving the detection of dengue virus. Moreover, the binding protein is not required to be produced by inducing hybridoma cells in mouse abdominal cavity, and thus it is simple in production and has more stable antibody function.

Abstract: Provided is an isolated binding protein including an antigen binding domain binding to an NS1 protein, and including specific heavy chain CDR and light chain CDR. The binding protein can specifically identify and bind to NS1, and has relatively high sensitivity and specificity, so as to detect dengue vims. Moreover, the binding protein does not need to be produced by injecting hybridoma cells into mouse peritoneal cavity, while simplifying production, thus stabilizing antibody functionality.

Abstract: A method and a device for localizing and lateralizing a brain functional region, an electronic apparatus, and a storage medium are provided herein, wherein the method for localizing and lateralizing the brain functional region comprises: acquiring brain structural magnetic resonance imaging data and brain functional magnetic resonance imaging data of a subject (201) based on the brain structural magnetic resonance imaging data and the brain functional magnetic resonance imaging data, determining a brain functional map of the subject (202), wherein the brain functional map comprises brain functional region identifiers of at least two brain functional regions and a corresponding set of voxels; for each of to-be-clinically-intervened voxels in a set of the to-be-clinically-intervened voxels, determining, based on the to-be-clinically-intervened voxel and the brain functional map, the brain functional region identifier corresponding to the to-be-clinically-intervened voxel (203); and determining a brain functiona

Abstract: Disclosed is an isolated binding protein including a cardiac troponin I (cTnI) antigen binding domain, and preparation and a use and the like of the binding protein. The antigen binding domain includes at least one complementarity determining region selected from an amino acid sequence defined in this article, or has at least 80% sequence identity with the complementarity determining region of the amino acid sequence and has KD?9.96×10?8 mol/L affinity with cTnI. The binding protein may be used in the detection field of the cTnI protein.

Abstract: A method for rapidly detecting viral genome size based on an agarose gel electrophoresis technology belongs to the technical field of virus detection. The kit for detecting the genome size includes a lysis buffer and a sample loading buffer solution, and includes the following raw material components: 5% lauryl sodium sulfate, 0.5 M sodium chloride, 50 mM ethylenediamine tetraacetic acid and 6× DNA gel sample loading buffer dye. By adopting the detection method, a plurality of tedious steps of the existing method are omitted, a clearer gel imaging result can be obtained, the detection time is greatly shortened, and the method is particularly suitable for rapidly detecting virus genome size of parvoviridae family. The method has important application value, and is more in line with the needs of virus detection and quality control research work in the field of gene therapy drug development.

Abstract: The present disclosure relates to the field of medical diagnosis, and specifically, relates to a synthetic peptide for detecting HIV-1. The synthetic peptide is obtained by mutating the amino acid sequence set forth as SEQ ID NO: 1. The synthetic peptide can better detect anti-HIV-1 antibodies, and can better avoid potential “false negative” and “false positive” results.

Abstract: Automatic container image registry selection is provided. A predefined number of top performing container image registries is selected from a top of a sorted list of a plurality of container image registries listed in descending order. A cluster of host nodes where a container is deployed is enabled to pull a same container image corresponding to the container utilizing different predefined pulling percentages from the predefined number of top performing container image registries. The cluster of host nodes utilizes a different predefined pulling percentage to pull the same container image from each respective top performing container image registry. A current real time average pulling speed of the cluster of host nodes for the same container image from each respective top performing container image registry of the predefined number of top performing container image registries is recorded over a defined time period.

Abstract: This disclosure describes systems, methods, and devices related to switchable adhesion. A switchable adhesion system may comprise a shape memory polymer having a shaped surface to enhance adhesion using a trigger and a force applied to the shape memory polymer, wherein the trigger is applied to alter characteristics of the shape memory polymer, and wherein the force is applied to deform the shape memory polymer while the trigger is applied. The system may further comprise a media tray connected to the shape memory polymer.

Abstract: A method and a device for localizing and lateralizing a brain functional region, an electronic apparatus, and a storage medium are provided herein, wherein the method for localizing and lateralizing the brain functional region comprises: acquiring brain structural magnetic resonance imaging data and brain functional magnetic resonance imaging data of a subject (201) based on the brain structural magnetic resonance imaging data and the brain functional magnetic resonance imaging data, determining a brain functional map of the subject (202), wherein the brain functional map comprises brain functional region identifiers of at least two brain functional regions and a corresponding set of voxels; for each of to-be-clinically-intervened voxels in a set of the to-be-clinically-intervened voxels, determining, based on the to-be-clinically-intervened voxel and the brain functional map, the brain functional region identifier corresponding to the to-be-clinically-intervened voxel (203); and determining a brain functiona

Abstract: A chimeric immunoglobulin is provided. It is obtained by fusing a first polypeptide and a second polypeptide, wherein the first polypeptide includes an IgG variable region located at the N terminal; and the second polypeptide includes an IgA CH2-CH3 region or an IgM CH3-CH4 region located at the C terminal. The immunoglobulin has higher titer, and when coated in a solid phase, it still has higher titer than that of an IgG monomer with the same valence, so it can be widely applied in the detection field.

Abstract: Provided is an isolated binding protein including an antigen binding domain binding to an NS1 protein, and comprising specific heavy chain CDR and light chain CDR. The binding protein can specifically identify and bind to NS1, and has relatively high sensitivity and specificity, so as to detect dengue virus. Moreover, the binding protein does not need to be produced by injecting hybridoma cells into mouse peritoneal cavity, while simplifying production, thus stabilizing antibody functionality.

Abstract: A device comprising one or more heat transfer laminates each including an electrode, a first dielectric layer on a first side of the electrode, and a second dielectric layer on a second side of the electrode; a plurality of flexible electrocaloric elements, each of the flexible electrocaloric elements including an electrocaloric material layer, a flexible electrode layer on the electrocaloric layer, one or more fixed portions each attached to one of heat transfer laminates, and a movable portion that is movable with respect to the one of the heat transfer laminates.

Abstract: Resource optimized forwarding of classified requests to different instances of a microservice is provided. The process includes obtaining classified requests to a microservice. The classified requests are classified based on different microservice resource consumption types. Further, the method includes forwarding the classified requests to instances of the microservice with different assigned resource configurations. The forwarding is based on the different microservice resource consumption types of the classified requests.

Abstract: An antibody against a novel coronavirus, and a reagent and a kit for detecting the novel coronavirus, which relate to the technical field of antibodies. The antibody against the novel coronavirus includes a heavy chain complementarity determinant region and a light chain complementarity determinant region. The antibody has good affinity for N protein of the novel coronavirus, and has good sensitivity and specificity for detecting the novel coronavirus. Antibody options are provided for detection of the novel coronavirus.

Abstract: The application relates to an HCV recombinant antigen and a mutant thereof. The application provides an HCV recombinant antigen, the HCV recombinant antigen including at least 1 NS3 antigen, wherein at least one cysteine of the NS3 antigen in positions 1192-1517 of an HCV amino acid sequence is mutated into G and/or A, and preferably mutated into A. The application further provides a nucleic acid encoding the HCV recombinant antigen, an expression vector including the nucleic acid, a host cell including the expression vector, a conjugate including the HCV recombinant antigen, and a kit including the HCV recombinant antigen.

Abstract: The present disclosure relates to an HCV recombinant antigen and use of the same. Provided is an HCV recombinant antigen, which includes at least two NS3 antigens, at least one NS4 antigen, and at least one core antigen. Further provided are a nucleic acid encoding the HCV recombinant antigen, an expression vector containing the nucleic acid, a host cell containing the expression vector, a conjugate containing the HCV recombinant antigen, and a kit containing the HCV recombinant antigen, and the like.

Abstract: A device comprising one or more heat transfer laminates each including an electrode, a first dielectric layer on a first side of the electrode, and a second dielectric layer on a second side of the electrode; a plurality of flexible electrocaloric elements, each of the flexible electrocaloric elements including an electrocaloric material layer, a flexible electrode layer on the electrocaloric layer, one or more fixed portions each attached to one of heat transfer laminates, and a movable portion that is movable with respect to the one of the heat transfer laminates.

Abstract: Disclosed is an isolated binding protein including a cardiac troponin I (cTnI) antigen binding domain, and preparation and a use and the like of the binding protein. The antigen binding domain includes at least one complementarity determining region selected from an amino acid sequence defined in this article, or has at least 80% sequence identity with the complementarity determining region of the amino acid sequence and has KD?9.96×10?8 mon affinity with cTnI. The binding protein may be used in the detection field of the cTnI protein.

Abstract: Disclosed is an isolated binding protein including a cardiac troponin I (cTnI) antigen binding domain, and preparation and a use and the like of the binding protein. The antigen binding domain includes at least one complementarity determining region selected from an amino acid sequence defined in this article, or has at least 80% sequence identity with the complementarity determining region of the amino acid sequence and has KD?7.51×10?8 mol/L affinity with cTnI. The binding protein may be used in the detection field of the cTnI.